Schrøder Henrik, Wacher Jeanette, Larsson Heidi, Rosthøj Steen, Rechnitzer Catherine, Petersen Bodil Laub, Carlsen Niels L T
Børneafdelingen, Århus Universitetshospital, Skejby, 8200 Århus N, Denmark.
Ugeskr Laeger. 2010 Oct 4;172(40):2761-5.
The aims of the present study were to analyze whether changes in incidence and mortality rates have taken place in Denmark during the period 1981-2005, and whether the distribution of known prognostic factors has changed during this period.
A total of 206 children below 15 years of age with neuroblastoma or ganglioneuroblastoma who were diagnosed in Denmark between 1981 and 2005.
The incidence was 8.68 per million children below 15 years of age (world standard 9.6) and 43.5 per million children below 12 months of age and these incidences have remained unchanged since 1970. The mortality rate has decreased steadily during the study period. The prognostic factors age, stage and site of primary tumour did not change during the study period and were not different from those reported by others. 32% of the children were below 12 months of age at diagnosis. 53% of the children had metastatic disease. The overall 5-year survival increased over the study period from 38% in 1981-1985 to 69% in 2001-2005. A significant increase in the survival of children > 12 months of age with stage 4 disease was also observed. Relapse/disease progression more than three years from diagnosis occurred in only 2% of patients. The median time from relapse to death was three months.
The survival of children with neuroblastoma in Denmark has increased significantly over the last 25 years.
本研究的目的是分析1981 - 2005年期间丹麦神经母细胞瘤和神经节神经母细胞瘤的发病率和死亡率是否发生了变化,以及在此期间已知预后因素的分布是否发生了改变。
共有206例15岁以下诊断为神经母细胞瘤或神经节神经母细胞瘤的丹麦儿童,诊断时间在1981年至2005年之间。
15岁以下儿童的发病率为每百万8.68例(世界标准为9.6例),12个月以下儿童的发病率为每百万43.5例,自1970年以来这些发病率一直保持不变。在研究期间死亡率稳步下降。预后因素年龄、原发肿瘤分期和部位在研究期间没有变化,与其他报告的情况无差异。32%的儿童在诊断时年龄小于12个月。53%的儿童患有转移性疾病。研究期间总体5年生存率从1981 - 1985年的38%提高到2001 - 2005年的69%。12个月以上患有4期疾病的儿童生存率也有显著提高。诊断后三年以上复发/疾病进展仅发生在2%的患者中。复发至死亡的中位时间为三个月。
在过去25年中,丹麦神经母细胞瘤患儿的生存率显著提高。